Aristoteles Giagounidis

Head of department

Katholisches Klinikum Koblenz

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Aristoteles Giagounidis is the Head of Department at Verbund Katholischer Kliniken Düsseldorf, Germany. His research primarily focuses on immune thrombocytopenia, acute myeloid leukemia, and myelodysplastic syndromes, as evidenced by his recent publications. He has contributed to significant advancements in the understanding and treatment of these conditions through various clinical trials and consensus proposals.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Arnold Ganser

Professor emeritus

Hannover Medical School

GERMANY

View details

sylvain thepot

Université d'Angers

FRANCE

View details

Nathalie Droin

Inserm u1183

FRANCE

View details

Eva Hoster

University Hospital, LMU Munich

GERMANY

View details

VALERIA SANTINI

ASSOCIATE PROFESSOR

University of Florence

ITALY

View details

lionel adès

Professor

FRANCE

View details

Christina Ganster

University Medical Center Göttingen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aristoteles Giagounidis

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy

Differential diagnosis and therapy of immune thrombocytopenia,Differenzialdiagnose und Therapie der Immunthrombozytopenie

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine

Pathophysiology and Diagnostics of Immune Thrombocytopenia,Pathophysiologie und Diagnostik der Immunthrombozytopenie

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER).

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Collaborators (7)

Arnold Ganser

sylvain thepot

Nathalie Droin

Eva Hoster

VALERIA SANTINI

lionel adès

Christina Ganster

Make your next move.